This ASX healthcare stock is up 12% in 2 days since All Ords inclusion: Should you buy?

The latest member of the All Ordinaries index is getting some love this week.

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

4DMedical Ltd (ASX: 4DX) shares are having another positive session.

At one stage today, the ASX healthcare stock was up as much as 7.5% to 78 cents.

When its shares hit that level, it meant they were up 12% in the space of just two days.

Why is this ASX healthcare stock jumping this week?

The catalyst for this rise has been news that the company's shares will be added to the All Ordinaries index later this month.

According to the update from S&P Dow Jones Indices, the medical research technology company is one of a number of new additions that will join the famous All Ordinaries index at the next quarterly rebalance on 18 March.

Furthermore, it will also join the S&P/ASX All Technology Index on the same day in the place of the ejected FINEOS Corporation Holdings PLC (ASX: FCL).

Is this good news?

Generally speaking, this can be very good news for a company's share price.

That's because fund managers often have restrictions on the shares they can buy. This is to stop them from risking client funds in speculative investments.

It's possible that some fund managers have investment mandates that allow them to invest in All Ordinaries shares. So, if they have been waiting to grab a piece of this ASX healthcare stock, this rebalance will allow them to finally press the buy button.

In addition, index funds that track the All Ordinaries or S&P/ASX All Technology Index will need to buy shares to reflect the changes.

Should you invest?

Bell Potter is very positive on the company, though it sees it as a higher risk option.

The broker currently has a speculative buy rating and $1.10 price target on the ASX healthcare stock.

This implies potential upside of over 40% for investors from current levels.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »